Study S000947

Additive Benefits of Semaglutide for Open-AngLe Glaucoma - an Opportunity for Neuroprotection

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT06792422
Acronym: ABSALON
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE4
Masking: QUADRUPLE
Status: RECRUITING
Enrollment: 126
Start: 2025-01
Primary completion: 2028-08
Lead sponsor: Glostrup University Hospital, Copenhagen
Conditions: Primary Open Angle Glaucoma (POAG); Open-Angle Glaucoma; Glaucoma
Interventions: DRUG:Oral semaglutide; DRUG:Placebo
Results posted: FALSE
Individual participant data sharing: NO
Secondary identifiers: OTHER_GRANT:NNF22OC0079544; CTIS:2024-518510-87-00

Registered primary outcomes

Photopic negative response of the electroretinogram after 6 months [From baseline to month 6.]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.